Case Study

Signant SmartSignals® RTSM: Randomization And Cohort Management, IP Inventory Management

GettyImages-1693748594 phone

Signant’s SmartSignals® RTSM solution played a pivotal role in assisting an innovative biopharmaceutical company in obtaining an FDA Orphan Drug designation for its cardiomyopathy medication.

The trial protocol necessitated an RTSM system capable of accommodating multiple cohorts, each with diverse drug combinations and visit schedules. Our setup team meticulously analyzed the protocol, devised intricate on-site titration, dispensation, and scheduling algorithms, and effectively communicated the system's design to the client.

Discover how Signant's SmartSignals RTSM solution facilitated the seamless transition of eligible patients from Phase II to Phase III, while also furnishing the client with real-time insights into patient dosing and inventory levels, thus ensuring timely and informed decision-making.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Tech Leader? Subscribe today.

Subscribe to Clinical Tech Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Tech Leader